AD brain organoids have also been employed as a drug platform, demonstrating a reduction in amyloid-β aggregates through the use of β- or γ-secretase modulators, along with mitigating the effect of tau pathology [194]. The gene discussed is MAPT; the disease is Alzheimer disease.